Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC vs FOLFIRI in Advanced Stomach Cancer
NCT00374036Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2005
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and irinotecan in gastric cancer (GC) and Gastric Cardia Adenocarcinoma, sponsored by Centre hospitalier universitaire de Toulouse. Started Jun 2005; status: completed.
02
Drugs
capecitabineirinotecan
03
Conditions
gastric cancer (GC)Gastric Cardia Adenocarcinoma
Beyond the preview
Go deeper on NCT00374036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00374036.